Annual Report

for the year ended 30 April 2014

Organic Growth

Innovation

Diversification

Chairman's Letter

Looking Forward

Dr. Peter Fellner Chairman

Consort Medical has delivered a year of solid trading performance in its core business, and has further expanded its future growth opportunities from both its development portfolio and its innovation pipeline.

Chief Executive's Review

Innovation Strength

Jonathan Glenn Chief Executive Officer

This year Consort Medical celebrated a number of 'firsts': the first year Bespak revenues surpassed £100m; the approval and launch of our first auto-injector; the award of our first MHRA commercial drug handling licence; the first development contract award for an Innovation centre-developed product (NAS030); and the unveiling of the first ....

Financial Review

Strong Performance

Richard Cotton Chief Financial Officer

Consort Medical delivered strong financial performance in the year with the organic revenue growth translating strongly into growth in operating margin, EBITDA and adjusted EPS. As expected, the year saw significant investment for future growth.

Highlights

  • Bespak revenue surpasses £100m;
  • Strong organic revenue growth of 5.2%, in particular from Chiesi NEXThaler®;
  • Growth in adjusted EPS of 8.5% to 48.3p per share;

QA video 2014

Q&A Video

Our Strategy for 2014